Jiangsu T-Mab Biopharma Co.,Ltd clinical trials
Acquired by Mabwell (Shanghai) Bioscience Co., Ltd., Sep 5, 2017 · source ↗
The registry lists 8 studies whose lead sponsor is Jiangsu T-Mab Biopharma Co.,Ltd. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Apr 3, 2018.
Before and after it joined Mabwell (Shanghai) Bioscience Co., Ltd.
- First submitted before Jiangsu T-Mab Biopharma Co.,Ltd became part of Mabwell (Shanghai) Bioscience Co., Ltd.
- 7
- First submitted after Jiangsu T-Mab Biopharma Co.,Ltd became part of Mabwell (Shanghai) Bioscience Co., Ltd.
- 1
- Unclear, or no submission date
- 0
By the date each study was first submitted to the registry. The registry lists today's sponsor name and keeps no history, so this says when a study was filed, not who filed it.
Registry sponsor names on this page
- Jiangsu T-Mab Biopharma Co.,Ltd8 studies
Something wrong with this grouping? Tell us on the Mabwell (Shanghai) Bioscience Co., Ltd. page.
Studies
Recruiting first, then most recently updated. Showing 8 of 8. All Mabwell (Shanghai) Bioscience Co., Ltd. studies →
- Safety Assessment of Repeated Administration of TK006 in Patients With Breast Cancer-related Bone MetastasesStatus unknownNCT03487055Phase 1
Sponsor listed in the registry: Jiangsu T-Mab Biopharma Co.,Ltd · First submitted after Jiangsu T-Mab Biopharma Co.,Ltd became part of Mabwell (Shanghai) Bioscience Co., Ltd.
- Assessment of Anti-RANKL Antibody in Post-menopausal WomenStatus unknownNCT03242512Phase 1
Sponsor listed in the registry: Jiangsu T-Mab Biopharma Co.,Ltd · First submitted before Jiangsu T-Mab Biopharma Co.,Ltd became part of Mabwell (Shanghai) Bioscience Co., Ltd.
- Evaluation the Pharmacokinetics, Safety, Tolerability of TK001 in Patients With Neovascular Age-related Macular DegenerationStatus unknownNCT02613559Phase 1
Sponsor listed in the registry: Jiangsu T-Mab Biopharma Co.,Ltd · First submitted before Jiangsu T-Mab Biopharma Co.,Ltd became part of Mabwell (Shanghai) Bioscience Co., Ltd.
- A Study of Multiple Intravitreal Injection TK001 in Patients With Neovascular Age-related Macular DegenerationStatus unknownNCT03021785Phase 1
Sponsor listed in the registry: Jiangsu T-Mab Biopharma Co.,Ltd · First submitted before Jiangsu T-Mab Biopharma Co.,Ltd became part of Mabwell (Shanghai) Bioscience Co., Ltd.
- Assessment of TK006 in Patients With Breast Cancer-related Bone MetastasesStatus unknownNCT03239756Phase 1
Sponsor listed in the registry: Jiangsu T-Mab Biopharma Co.,Ltd · First submitted before Jiangsu T-Mab Biopharma Co.,Ltd became part of Mabwell (Shanghai) Bioscience Co., Ltd.
- Tolerability and Pharmacokinetics(PK)/Pharmacodynamics(PD) Study of GW003 in Healthy SubjectsCompletedNCT02643901Phase 1
Sponsor listed in the registry: Jiangsu T-Mab Biopharma Co.,Ltd · First submitted before Jiangsu T-Mab Biopharma Co.,Ltd became part of Mabwell (Shanghai) Bioscience Co., Ltd.
- Study to Assess the Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics of GW003 in Patients With Breast CancerStatus unknownNCT02725606Phase 1
Sponsor listed in the registry: Jiangsu T-Mab Biopharma Co.,Ltd · First submitted before Jiangsu T-Mab Biopharma Co.,Ltd became part of Mabwell (Shanghai) Bioscience Co., Ltd.
- Safety and Pharmacokinetic(PK) Study of GW003 to Metastatic TumorsCompletedNCT02156388Phase 1
Sponsor listed in the registry: Jiangsu T-Mab Biopharma Co.,Ltd · First submitted before Jiangsu T-Mab Biopharma Co.,Ltd became part of Mabwell (Shanghai) Bioscience Co., Ltd.